Status:
RECRUITING
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Lead Sponsor:
Alberta Health services
Conditions:
Neuroendocrine Tumors (NET)
Eligibility:
All Genders
18-100 years
Brief Summary
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT...
Detailed Description
The purpose of the current study will be to evaluate the usefulness of 68Ga-HA-DOTATATE compared to current standard anatomical imaging including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, a...
Eligibility Criteria
Inclusion Criteria:
- Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
- Age greater than or equal to 18 years.
- Able and willing to follow instructions and comply with the protocol.
- Provide written informed consent prior to participation in the study.
- Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor
Exclusion Criteria:
- Nursing or pregnant females.
- Age less than 18 years.
- Surgery in the area of interest within the preceding 2 months.
Key Trial Info
Start Date :
February 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05673031
Start Date
February 1 2023
End Date
January 1 2027
Last Update
January 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Center 1403 29 St NW
Calgary, Alberta, Canada, T2N 2T9